Evidence map›Paper›PMID 40640749›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Rhein alleviates hepatic steatosis in NAFLD mice by activating the AMPK/ACC/SREBP1 pathway to enhance lipid metabolism.

Weiwei Dai, Qishu Hou, Jifeng Ye

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Sequential Fractionation ofFoods (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Weiwei DaiDepartment of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, No. 109 West Road, Lucheng District, Wenzhou, 325000, Zhejiang, China.
Qishu HouDepartment of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, No. 109 West Road, Lucheng District, Wenzhou, 325000, Zhejiang, China.
Jifeng YeDepartment of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, No. 109 West Road, Lucheng District, Wenzhou, 325000, Zhejiang, China. YeJifeng2628@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is a common metabolic liver disorder characterized by excessive lipid accumulation. The 5'-adenosine monophosphate-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC)/sterol regulatory element-binding protein 1 (SREBP1) pathway plays a pivotal role in regulating lipid metabolism. Rhein, a natural compound, has demonstrated hepatoprotective potential; however, its mechanism of action in NAFLD remains unclear. This study aimed to investigate whether rhein ameliorates NAFLD through modulation of the AMPK/ACC/SREBP1 pathway.

methodsA murine NAFLD model was established using a high-fat diet (HFD). Mice were treated with varying doses of rhein, and their body weight, liver, kidney, and retroperitoneal fat weights were recorded. Liver pathology was assessed by histological examination and Oil Red O staining. Serum lipid profiles, liver function biomarkers, and inflammatory cytokine levels were measured. Western blotting was employed to analyze the expression and phosphorylation of AMPK pathway-related proteins (AMPK, ACC, and SREBP1). To validate the involvement of this pathway, AMPK-IN-3 was intraperitoneally administered in combination with high-dose rhein to a subset of HFD-fed mice.

resultsRhein treatment significantly reduced body weight gain, organ weights, hepatic lipid accumulation, serum cholesterol and triglyceride levels, and the expression of inflammatory cytokines in NAFLD mice. It also improved liver function markers, enhanced AMPK phosphorylation, promoted ACC phosphorylation, and inhibited SREBP1 expression. Notably, co-treatment with AMPK-IN-3 attenuated these beneficial effects, confirming the mechanistic involvement of the AMPK/ACC/SREBP1 pathway.

conclusionRhein confers protective effects against HFD-induced NAFLD by activating the AMPK/ACC/SREBP1 signaling pathway, thereby enhancing hepatic lipid metabolism, reducing steatosis, and alleviating liver injury and inflammation. These findings suggest that rhein may serve as a promising therapeutic candidate for NAFLD.

Indexed as

Acetyl-CoA CarboxylaseAMP-Activated Protein KinasesAnthraquinonesLipid MetabolismNon-alcoholic Fatty Liver DiseaseSignal TransductionSterol Regulatory Element Binding Protein 1AnimalsDiet, High-FatDisease Models, AnimalLiverMaleMiceMice, Inbred C57BLAcetyl-CoA CarboxylaseAMP-Activated Protein KinasesAnthraquinonesrheinSrebf1 protein, mouseSterol Regulatory Element Binding Protein 15'-adenosine monophosphate-activated protein kinase signaling pathwayAcetyl-coa carboxylaseNon-alcoholic fatty liver diseaseRheinSterol regulatory element-binding protein 1

Identifiers

PMID40640749
PMCPMC12247347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.